TRANSFUSIUS
LIVE

Serial Number

79407821

Owner

Haema GmbH

Attorney

Deborah L. Shapiro

Filing Date

Jun 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TRANSFUSIUS Trademark

Serial Number: 79407821 • Registration: 7910357

TRANSFUSIUS is a trademark filed by Haema GmbH on June 21, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Haema GmbH (13 trademarks)

Landsteinerstraße 1

Entity Type: 98

Haema AG (13 trademarks)

Deutscher Platz 5e

Entity Type: 98

Trademark Details

Filing Date

June 21, 2024

Registration Date

August 26, 2025

Published for Opposition

July 8, 2025

Goods & Services

Advertising services; Arranging advertising events, namely, organizing events for advertising purposes; Advertising services for others, namely, developing advertising campaigns for others for attracting donors of blood and blood components; Advertising services to create brand identity for others in all media, including radio, television, cinema, print, videotext, on-line and via teletext advertising; Promoting the goods and services of others by arranging for sponsors provide promotional sponsorships by affiliating their goods and services with sports exhibitions, art shows, live music concerts

Drugs, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; Living cells and cell fragments for medical purposes, namely, red blood cell concentrates; Living cells and cell fragments for medical purposes, namely, platelet concentrates; Living cells for medical purposes, namely, leukocyte preparations of white bloods cells for medical purposes; blood plasma, blood for medical and medical diagnostic purposes; blood cells for medical purposes; Blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood, blood fractions and blood components for medical, therapeutic, and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components for medical use, namely, blood plasma, blood substitutes for human use; Blood plasma; Cells for medical use, namely, blood cell preparations; Sanitary preparations for medical purposes; Finished medical products, namely, human blood for medical purposes and blood plasma; Pharmaceutical preparations for the treatment of bleeding disorders, heart disease, cancer; Immunotherapeutic and immunoprophylactic preparations in the nature of blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Living cells for medical purposes, namely, leukocyte preparations; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates, quarantine plasma, fractionated plasma; clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; Pharmaceutical products and preparations, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and bloods substitutes for human use and pharmaceutical preparations for the treatment of blood diseases and disorders; Pharmaceutical blood plasma preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases, blood disorders; Cell material for autotransplantation and autotransfusion, cells for medical use; Cell material for transplantation and transfusion, namely, cells for medical use; Cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical purposes

Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; Providing temporary use of online, non-downloadable software for accessing patient treatment databases and donor databases; Providing technological and scientific information about scientific laboratory services and blood banks, in particular medical research laboratories; Providing of scientific information derived from analysis of medical diagnostic results; Blood analysis services for scientific research purposes; Scientific laboratory services; Chemical laboratories and medical research laboratories; Scientific research in the field of physics; Chemistry services, namely, chemical analysis, chemical laboratories; Chemical analysis; Scientific testing services, namely, blood testing for scientific research purpose; Blood testing for scientific research purposes, with said testing entailing the filtration, separation and centrifugation of blood; Laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; Development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; Database development services, namely, creation of medical databases in digital form; Scientific and medical research in the medical and pharmaceutical fields; Scientific and medical research in the field of chemistry and biology; Development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures, and medical instrument procedures; Data processing services, namely, technical and scientific registration and processing of patient treatment data and donor data in databases; Scientific laboratory services

Medical analysis services for diagnostic and treatment purposes provided by medical laboratories in connection with blood and plasma donation and clinical medical consultations in connection with the same; Pharmacy advice, namely, providing medical advice in the field of pharmaceuticals; providing of medical information in relation to blood donation centres; Providing of medical and pharmaceutical support via telephone, namely, providing medical information; Medical services featuring blood fractionation or blood transfusion for medical purposes; Medical services in the nature of blood sampling or collection; Blood examination in the nature of medical blood analysis services for diagnostic treatment purposes; medical assistance; blood bank services; Blood bank services in the nature of blood donation centres; Blood bank services in the nature of blood extraction stations; Services in the field of immunotherapy, namely, medical care; Nursing home services; Medical care, namely, immunotherapy; Providing medical information, namely, medical diagnostic information through medical results; Medical care, namely, conducting medical diagnostics within the framework of conducting medical examinations; Blood bank services, namely, conducting of blood donation, including platelet donations, SDR donation being erythrocyte, whole blood donation, plasma donation, and autologous donation being multiple type of cellular donations from an individual; Medical care, namely, execution of medical and clinical examination services; nutrition consultation; Providing medical opinions in the nature of medical advice in the field of weight loss, dermatology, hematology; health counseling; Medical services, namely, transfusion or transplantation of blood and blood components; Medical services; Rental of medical equipment; Rental of medical equipment in the nature of medical diagnostic instruments and apparatus for medical purposes

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 9, 2026 OPNX
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 2, 2026 FINO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2026 OPNR
FINAL DISPOSITION NOTICE SENT TO IB
Mar 14, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 14, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 26, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 26, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 26, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2025 TROA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 18, 2025 ADCH
REFUSAL PROCESSED BY IB
Feb 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 4, 2025 RFCS
REFUSAL PROCESSED BY MPU
Feb 4, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 31, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 30, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 21, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 28, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 28, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 24, 2024 REPR